Status:
COMPLETED
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
Lead Sponsor:
Association Asthma, Bulgaria
Collaborating Sponsors:
UCB Pharma
Conditions:
Chronic Urticaria
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Allen Kaplan is a prominent American allergist with the reputation of leader in the field of chronic urticaria. He advocates treatment with first generation hydroxyzine, which he considers at least as...
Detailed Description
Study design: The study will involve two distinct parts (flow chart): 1. In-hospital assessment of effectiveness and tolerability of 10 \& 20 mg levocetirizine vs. 100 \& 200 mg hydroxyzine in subje...
Eligibility Criteria
Inclusion
- 24 randomized patients of either sex,
- ≥18 years of age.
- Included patients should have at least a 6-week documented history of urticaria with intake of 15-30 mg Prednisolon.
Exclusion
- Patients with physically induced urticarias;
- pregnancy and lactation;
- any chronic disease requiring daily other drug treatment including, antihypertensives, antipsychotics and antidepressants;
- other skin disease
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01250652
Start Date
March 1 2011
End Date
March 1 2013
Last Update
July 17 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Sofia, Department of Allergology
Sofia, Bulgaria, 1431